Aug 18th, 2019 - The U.S. Food and Drug Administration today approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia. “This new drug provides another option for the treatment of patients with community-acquired bacterial pneumonia, a serious disease,” said Ed Cox, M.D., M.P.H., director of FDA’s Office of Antimicrobial Products. “For managing this serious disease, it is impor...
Jul 14th, 2019 - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder, a combination therapy digital inhaler with built-in sensors that connects to a companion mobile application to provide information on inhaler use to people with asthma....
Adempas (riociguat). Visit Adempas-US.com to see full safety and prescribing information, including Boxed Warning. Learn about Adempas and the Aim Patient Support Program.
ADCIRCA is a trademark of Eli Lilly and Company. http://pi.lilly.com/us/adcirca-ppi.pdf. Please see Important Safety Information and Full Prescribing Information.
The Aerobika® OPEP device opens weak or collapsed airways to mobilize and assist mucociliary clearance to the upper airways where it can be coughed out. ... The Aerobika® OPEP device increases the natural process within the lungs to bring up mucus. ... The Aerobika® OPEP device provides ...
It contains tools and resources so your patients have access to the chamber that is right for them. You can receive a Direct-to-Home Delivery Kit by ordering an ...
ADVAIR DISKUS is contraindicated for primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are ...
Learn about the first and only FDA-approved dry-powder rescue inhaler that requires no hand-breath coordination during inhalation and compare it to other rescue inhalers.
Find out more about DALIRESP and how it may help patients with severe COPD that are already using bronchodilators. DALIRESP may reduce the risk of exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
Breo Ellipta. ... BREO is for adult patients with asthma uncontrolled on a long-term control medication (eg, ICS) or whose disease warrants an ICS/LABA (inhaled corticosteroid/long-acting beta2-adrenergic agonist). BREO is NOT indicated for the relief of acute bronchospasm.
Learn about BROVANA® (arformoterol tartrate), an inhaled maintenance treatment used with a nebulizer system for controlling symptoms of COPD.
COMBIVENT RESPIMAT is indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to ...
Once-daily INCRUSE is a prescription medicine used long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing.
Learn more about FASENRA for treatment of eosinophilic asthma in patients with severe asthma. FASENRA is designed for eosinophil depletion in patients 12 years or older with severe eosinophilic asthma.
Find information about Letairis and the AMBITION trial: design, results, dosing, prescribing information, guidelines, resources.
PRADAXA is the only NOAC with a specific reversal, available in all 50 states. See how PRADAXA compares to warfarin, and find dosing and coverage information. Please see Important Safety Information and full Prescribing Information, including boxed warning.
Visit the official HCP website for OFEV (nintedanib), a treatment option for your patients with idiopathic pulmonary fibrosis (IPF), by Boehringer Ingelheim. Adverse reactions may occur. Please see full prescribing information, including patient information, and important safety information on this website.
ProAir® RespiClick Official Site for healthcare professionals. Find safety, efficacy, formulary, dosage, prescribing information, and more.
Use DYLOJECT at the lowest daily dose for the shortest duration possible to minimize risk of CV, GI and hepatic adverse events. Contraindications. DYLOJECT is contraindicated in patients with: Known hypersensitivity to diclofenac or any components of the drug product. History of asthma, urticaria, or other allergic-type ...
Information for health care professionals about DULERA, an ICS/LABA combination therapy for the treatment of asthma in patients 12 years of age and older.